Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Study Overview

This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.

Study Description

A Phase II Study of TAK-228 in patients with previously treated metastatic renal cell carcinoma

  • ClinicalTrials.gov Identifier: NCT03097328
  • Protocol Number: 16-527
  • Principal Investigator: David McDermott

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000